In PATH, a randomized, double-blind trial and the largest CIDP trial to date, the primary outcome measure was met: Subcutaneous immunoglobulin (SCIg) reduced the number of relapses or withdrawals more than placebo in patients with CIDP who responded to IVIg, an established treatment for CIDP. The takeaway from this landmark trial is that patients with CIDP who have stabilized with IVIg may switch to treatment with SCIg.
Learn more about treatment with immunomodulatory/immunosuppressive agents.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Jafar Kafaie. Fast Five Quiz: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Management - Medscape - Jun 24, 2021.